2022 Project: University of California, San Francisco (UCSF)

Characterization of host and immune responses to different SARS-CoV-2 variants and association with disease severity

What to know

The team at UCSF plans to combine whole-genome sequencing for SARS-CoV-2 variants with host transcriptome and antibody analyses to develop models for predicting poor outcomes of SARS-CoV-2 infection and likelihood of vaccine breakthrough or re-infection.

Decorative image with words "2022" and "SARS-CoV-2"

Findings on SARS-CoV-2 surveillance and investigations

This project provided a systems-level view of immune responses and tissue damage in COVID-19 and MIS-C which could inform future development of new disease biomarkers.1

Awarded in 2022, this project is still in progress.

Print
Content Source:
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
  1. Nucleic acid biomarkers of immune response and cell and tissue damage in children with COVID-19 and MIS-C - PMC (nih.gov) Cell Rep Med